Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Vascular Surgery

Free Subscription Articles published in Eur Heart J Retrieve available abstracts of 168 articles: HTML format

Single Articles

August 2022
1. RONG D, Zhang H, Guo W
   Aortic arch aneurysm isolated by percutaneous total endovascular arch replacement.
   Eur Heart J. 2022;43:2905.
   PubMed    
   
   
   July 2022
2. CREA F
   The challenge of risk stratification in aortic aneurysms, congenital heart disease, and coronary bypass surgery.
   Eur Heart J. 2022;43:2343-2346.
   PubMed    
   
   
   
3. GAUDINO M, Farkouh ME, Stone GW
   Left main revascularization: an evidence-based reconciliation.
   Eur Heart J. 2022;43:2421-2424.
   PubMed    
   
   
   
4. RYCHIK J
   You can only change what you measure: an argument for more detailed characterization in the Fontan circulation.
   Eur Heart J. 2022;43:2385-2387.
   PubMed    
   
   
   
5. ELEFTERIADES JA, Zafar MA, Ziganshin BA
   Nationwide collaboration produces valuable data regarding arch and descending aorta.
   Eur Heart J. 2022;43:2370-2372.
   PubMed    
   
   
   
6. INAI K, Inuzuka R, Ono H, Nii M, et al
   Predictors of long-term mortality among perioperative survivors of Fontan operation.
   Eur Heart J. 2022;43:2373-2384.
   PubMed     Abstract available
   
   
   June 2022
7. ZHANG Y, Yang P, Lu C, Hu J, et al
   Hybrid aortic arch repair for unibody single-branched endograft induced retrograde aortic dissection.
   Eur Heart J. 2022;43:2342.
   PubMed    
   
   
   
8. KHAIRY P, Silka MJ, Moore JP, DiNardo JA, et al
   Sudden cardiac death in congenital heart disease.
   Eur Heart J. 2022;43:2103-2115.
   PubMed     Abstract available
   
   
   
9. ZHANG X, Fang Z, Zhang H, Ma X, et al
   Fibromuscular dysplasia: a rare adult case with aortic arch coarctation and bilateral subclavian artery and internal carotid artery stenosis.
   Eur Heart J. 2022 Jun 2. pii: 6599045. doi: 10.1093.
   PubMed    
   
   
   April 2022
10. BATRA G, Aktaa S, Wallentin L, Maggioni AP, et al
    Data standards for acute coronary syndrome and percutaneous coronary intervention: the European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart).
    Eur Heart J. 2022 Apr 5. pii: 6563567. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2022
11. CREA F
    Percutaneous coronary intervention vs. coronary artery bypass graft: the saga continues.
    Eur Heart J. 2022;43:1273-1276.
    PubMed    
    
    
    
12. BYRNE RA, Rai H, Colleran R
    Amphilimus-eluting stents in coronary artery disease: finally, a sweet spot for patients with diabetes mellitus?
    Eur Heart J. 2022;43:1331-1333.
    PubMed    
    
    
    
13. ALMARZOOQ ZI, Yeh RW
    'State of the Art' PCI: bridging the implementation gap.
    Eur Heart J. 2022;43:1317-1319.
    PubMed    
    
    
    
14. ROMAGUERA R, Salinas P, Gomez-Lara J, Brugaletta S, et al
    Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial.
    Eur Heart J. 2022;43:1320-1330.
    PubMed     Abstract available
    
    
    
15. HAN Y, Li Y
    Adherence to P2Y12 inhibitors in acute coronary syndrome after a percutaneous coronary intervention: what can we improve?
    Eur Heart J. 2022 Mar 17. pii: 6549760. doi: 10.1093.
    PubMed    
    
    
    
16. TURGEON RD, Koshman SL, Dong Y, Graham MM, et al
    P2Y12 inhibitor adherence trajectories in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prognostic implications.
    Eur Heart J. 2022 Mar 17. pii: 6549798. doi: 10.1093.
    PubMed     Abstract available
    
    
    
17. THYGESEN K, Jaffe AS
    Revisiting the definition of perioperative myocardial infarction after coronary artery bypass grafting.
    Eur Heart J. 2022 Mar 17. pii: 6549761. doi: 10.1093.
    PubMed    
    
    
    February 2022
18. LIUZZO G, Volpe M
    Percutaneous coronary intervention vs. coronary artery bypass graft for left main coronary artery disease: a never-ending debate.
    Eur Heart J. 2022 Feb 21. pii: 6533241. doi: 10.1093.
    PubMed    
    
    
    
19. OMRAN H, Deutsch MA, Groezinger E, Zittermann A, et al
    High-sensitivity cardiac troponin I after coronary artery bypass grafting for post-operative decision-making.
    Eur Heart J. 2022 Feb 15. pii: 6528587. doi: 10.1093.
    PubMed     Abstract available
    
    
    
20. POLZL L, Thielmann M, Cymorek S, Nagele F, et al
    Impact of myocardial injury after coronary artery bypass grafting on long-term prognosis.
    Eur Heart J. 2022 Feb 9. pii: 6525341. doi: 10.1093.
    PubMed     Abstract available
    
    
    
21. ESCANED J, Jaffer FA, Mehilli J, Mehran R, et al
    The year in cardiovascular medicine 2021: interventional cardiology.
    Eur Heart J. 2022;43:377-386.
    PubMed     Abstract available
    
    
    January 2022
22. RYAN M, Morgan H, Chiribiri A, Nagel E, et al
    Myocardial viability testing: all STICHed up, or about to be REVIVED?
    Eur Heart J. 2022;43:118-126.
    PubMed     Abstract available
    
    
    
23. QUADRI G, Tomassini F, Cerrato E, Varbella F, et al
    Emergency treatment of a giant coronary aneurysm: percutaneous intervention with coronary and peripheral tools.
    Eur Heart J. 2022;43:168.
    PubMed    
    
    
    December 2021
24. WANG R, Serruys PW, Gao C, Hara H, et al
    Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease.
    Eur Heart J. 2021;43:56-67.
    PubMed     Abstract available
    
    
    
25. BODEN WE, De Caterina R, Taggart DP
    Is there equivalence between PCI and CABG surgery in long-term survival of patients with diabetes? Importance of interpretation biases and biological plausibility.
    Eur Heart J. 2021;43:68-70.
    PubMed    
    
    
    
26. BEHRENDT CA
    Higher long-term mortality after endovascular vs. open-surgical revascularization of peripheral artery disease in Australia and New Zealand?
    Eur Heart J. 2021;43:41-43.
    PubMed    
    
    
    
27. PARVAR SL, Ngo L, Dawson J, Nicholls SJ, et al
    Long-term outcomes following endovascular and surgical revascularization for peripheral artery disease: a propensity score-matched analysis.
    Eur Heart J. 2021;43:32-40.
    PubMed     Abstract available
    
    
    
28. LOZANO I, Vegas JM, Rondan J
    Percutaneous intervention in patients with cancer: can we offer an improvement in safety?
    Eur Heart J. 2021;42:4981.
    PubMed    
    
    
    
29. GALLI M, Benenati S, Franchi F, Rollini F, et al
    Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.
    Eur Heart J. 2021 Dec 16. pii: 6464193. doi: 10.1093.
    PubMed     Abstract available
    
    
    
30. CREA F
    Percutaneous coronary interventions: more complex than fixing stenoses.
    Eur Heart J. 2021;42:4607-4611.
    PubMed    
    
    
    
31. NAVARESE EP, Andreotti F
    Cardiac mortality, adequate power, and objective inclusion of the entire evidence are key to accurately define the long-term effect of revascularisation vs. medical therapy alone in stable coronary syndromes.
    Eur Heart J. 2021;42:4699-4700.
    PubMed    
    
    
    
32. WHITE HD
    Cardiac death should be the primary endpoint for revascularization trials and meta-analyses.
    Eur Heart J. 2021;42:4697-4698.
    PubMed    
    
    
    
33. PARKER WAE, Storey RF
    Ticagrelor monotherapy in CKD: better safety at what price?
    Eur Heart J. 2021;42:4694-4696.
    PubMed    
    
    
    
34. ABELLAS-SEQUEIROS M, Pardo Sanz A, Sanchez-Recalde A, Sanmartin-Fernandez M, et al
    Traumatic coronary artery dissection with total occlusion of left descending coronary artery: to stent or not to stent.
    Eur Heart J. 2021;42:4701.
    PubMed    
    
    
    
35. BROWN DL, Boden WE
    Impact of revascularisation on outcomes in chronic coronary syndromes: a new meta-analysis with the same old biases?
    Eur Heart J. 2021;42:4652-4655.
    PubMed    
    
    
    November 2021
36. GASBARRINO K, Di Iorio D, Daskalopoulou SS
    Importance of sex and gender in ischaemic stroke and carotid atherosclerotic disease.
    Eur Heart J. 2021 Nov 26. pii: 6444192. doi: 10.1093.
    PubMed     Abstract available
    
    
    
37. EGGERS KM, James SK, Lindahl B
    Myocardial infarction after elective percutaneous coronary intervention-which cardiac troponin cut-off to use?
    Eur Heart J. 2021 Nov 24. pii: 6438090. doi: 10.1093.
    PubMed    
    
    
    
38. MARK N
    Healing the rift over left main revascularization.
    Eur Heart J. 2021;42:4509-4511.
    PubMed    
    
    
    
39. LIUZZO G, Patrono C
    Does abbreviated dual antiplatelet therapy after PCI provide a clinically meaningful trade-off between bleeding and ischaemic events in patients at high risk for bleeding?
    Eur Heart J. 2021;42:4418-4419.
    PubMed    
    
    
    
40. KAWAMURA M, Monta O
    Spontaneous true lumen expansion in chronic type B aortic dissection.
    Eur Heart J. 2021;42:4403.
    PubMed    
    
    
    October 2021
41. ESCANED J, Cao D, Baber U, Nicolas J, et al
    Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR.
    Eur Heart J. 2021 Oct 18. pii: 6400337. doi: 10.1093.
    PubMed     Abstract available
    
    
    
42. FERNANDO H, Duong T, Huynh K, Noonan J, et al
    Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial.
    Eur Heart J. 2021;42:4025-4036.
    PubMed     Abstract available
    
    
    
43. LECHNER I, Reindl M, Tiller C, Holzknecht M, et al
    Impact of COVID-19 pandemic restrictions on ST-elevation myocardial infarction: a cardiac magnetic resonance imaging study.
    Eur Heart J. 2021 Oct 11. pii: 6386704. doi: 10.1093.
    PubMed     Abstract available
    
    
    
44. BANNING AP, Serruys P, De Maria GL, Ryan N, et al
    Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: final results of the SYNTAX II study.
    Eur Heart J. 2021 Oct 7. pii: 6383065. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2021
45. HAN Y
    Long-term outcomes of new-generation coronary stents in China.
    Eur Heart J. 2021 Sep 18. pii: 6372216. doi: 10.1093.
    PubMed    
    
    
    
46. PETERS SAE, Kluin J
    Why do women do worse after coronary artery bypass grafting?
    Eur Heart J. 2021 Sep 15. pii: 6370651. doi: 10.1093.
    PubMed    
    
    
    
47. ERLINGE D, Gotberg M
    We need intracoronary physiology guidance before percutaneous coronary intervention, but do we need it post-stenting?
    Eur Heart J. 2021 Sep 4. pii: 6364082. doi: 10.1093.
    PubMed    
    
    
    August 2021
48. YANG Q, Sun D, Pei C, Zeng Y, et al
    LDL cholesterol levels and in-hospital bleeding in patients on high-intensity antithrombotic therapy: findings from the CCC-ACS project.
    Eur Heart J. 2021;42:3175-3186.
    PubMed     Abstract available
    
    
    
49. CERRATO E, Giacobbe F, Quadri G, Macaya F, et al
    Antiplatelet therapy in patients with conservatively managed spontaneous coronary artery dissection from the multicentre DISCO registry.
    Eur Heart J. 2021;42:3161-3171.
    PubMed     Abstract available
    
    
    
50. STEFANINI GG, Briguori C, Cao D, Baber U, et al
    Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD.
    Eur Heart J. 2021 Aug 23. pii: 6356261. doi: 10.1093.
    PubMed     Abstract available
    
    
    
51. NICHOLLS M
    Mark Nicholls speaks to Professor Eric Durand and Professor Remi Sabatier about Europe's first remote robotic-assisted angioplasty procedure.
    Eur Heart J. 2021;42:3033-3035.
    PubMed    
    
    
    
52. DAVIERWALA PM, Gao C, Thuijs DJFM, Wang R, et al
    Single or multiple arterial bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel or left main coronary artery disease.
    Eur Heart J. 2021 Aug 18. pii: 6354120. doi: 10.1093.
    PubMed     Abstract available
    
    
    
53. CREA F
    Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy.
    Eur Heart J. 2021;42:2973-2985.
    PubMed    
    
    
    
54. ZEYMER U, Ludman P, Danchin N, Kala P, et al
    Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology.
    Eur Heart J. 2021 Aug 14. pii: 6352178. doi: 10.1093.
    PubMed     Abstract available
    
    
    
55. GAUDINO M, Di Franco A, Alexander JH, Bakaeen F, et al
    Sex differences in outcomes after coronary artery bypass grafting: a pooled analysis of individual patient data.
    Eur Heart J. 2021 Aug 2. pii: 6333765. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2021
56. KOSYAKOVSKY LB, Austin PC, Ross HJ, Wang X, et al
    Early invasive coronary angiography and acute ischaemic heart failure outcomes.
    Eur Heart J. 2021 Jul 30. pii: 6331345. doi: 10.1093.
    PubMed     Abstract available
    
    
    
57. GOROG DA, Navarese EP, Andreotti F
    Should we consider low LDL-cholesterol a marker of in-hospital bleeding in patients with acute coronary syndrome undergoing percutaneous coronary intervention?
    Eur Heart J. 2021 Jul 29. pii: 6330652. doi: 10.1093.
    PubMed    
    
    
    
58. COLLISON D, Didagelos M, Aetesam-Ur-Rahman M, Copt S, et al
    Post-stenting fractional flow reserve vs coronary angiography for optimisation of percutaneous coronary intervention: TARGET-FFR trial.
    Eur Heart J. 2021 Jul 19. pii: 6323924. doi: 10.1093.
    PubMed     Abstract available
    
    
    
59. MADHAVAN MV, Howard JP, Naqvi A, Ben-Yehuda O, et al
    Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials.
    Eur Heart J. 2021;42:2643-2654.
    PubMed     Abstract available
    
    
    
60. NI B, Gu J, Li M, Shao Y, et al
    Emergent endovascular repair of a huge aortic arch aneurysm with aortopulmonary fistula secondary to Takayasu's arteritis.
    Eur Heart J. 2021;42:2712.
    PubMed    
    
    
    
61. ABDELWAHED YS, Schatz AS, Landmesser U, Skurk C, et al
    'Small bifurcation?' CT myocardial mass volume measurements change therapeutic strategy in coronary artery disease.
    Eur Heart J. 2021;42:2713-2714.
    PubMed    
    
    
    
62. MAMAS MA
    Decision making in percutaneous coronary intervention in patients with cancer: balancing ischaemic and bleeding risk.
    Eur Heart J. 2021 Jul 13. pii: 6319849. doi: 10.1093.
    PubMed    
    
    
    
63. ONO M, Garg S, Onuma Y, Serruys PW, et al
    Coronary artery bypass grafting versus percutaneous coronary intervention in ischaemic heart failure. Can reliable treatment decisions in high-risk patients be based on non-randomized data?
    Eur Heart J. 2021 Jul 1. pii: 6311994. doi: 10.1093.
    PubMed    
    
    
    May 2021
64. BULLUCK H, Paradies V, Barbato E, Baumbach A, et al
    Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardio
    Eur Heart J. 2021 May 31. pii: 6290281. doi: 10.1093.
    PubMed     Abstract available
    
    
    
65. VOLZ S, Redfors B, Angeras O, Ioanes D, et al
    Long-term mortality in patients with ischaemic heart failure revascularized with coronary artery bypass grafting or percutaneous coronary intervention: insights from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
    Eur Heart J. 2021 May 23. pii: 6282431. doi: 10.1093.
    PubMed     Abstract available
    
    
    
66. CHIN CY, Huang SC, Wang JK, Chen CA, et al
    A bleeding Blalock-Taussig shunt.
    Eur Heart J. 2021;42:2022.
    PubMed    
    
    
    
67. HILDICK-SMITH D, Egred M, Banning A, Brunel P, et al
    The European bifurcation club Left Main Coronary Stent study: a randomized comparison of stepwise provisional vs. systematic dual stenting strategies (EBC MAIN).
    Eur Heart J. 2021 May 18. pii: 6276782. doi: 10.1093.
    PubMed     Abstract available
    
    
    
68. LANSKY A, Chun H, Pietras C, Hussain Y, et al
    Refining drug-eluting stent technologies: from engineering to basic science.
    Eur Heart J. 2021;42:1770-1772.
    PubMed    
    
    
    April 2021
69. BODEN WE, Stone PH
    To stent or not to stent? Treating angina after ISCHEMIA-why a conservative approach with optimal medical therapy is the preferred initial management strategy for chronic coronary syndromes: insights from the ISCHEMIA trial.
    Eur Heart J. 2021;42:1394-1400.
    PubMed    
    
    
    
70. GAUDINO M, Di Franco A, Bhatt DL, Alexander JH, et al
    The association between coronary graft patency and clinical status in patients with coronary artery disease.
    Eur Heart J. 2021;42:1433-1441.
    PubMed     Abstract available
    
    
    
71. DING D, Huang J, Westra J, Cohen DJ, et al
    Immediate post-procedural functional assessment of percutaneous coronary intervention: current evidence and future directions.
    Eur Heart J. 2021 Apr 5. pii: 6211340. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2021
72. VITALE N, Lucarelli K, Di Bari N, Milano AD, et al
    Anomalous origin of a grafted left internal mammary artery from the deep brachial artery.
    Eur Heart J. 2021;42:1182.
    PubMed    
    
    
    
73. MARENZI G, Cosentino N, Cardinale D
    Ischaemic and bleeding risk in cancer patients undergoing PCI: another brick in the wall.
    Eur Heart J. 2021;42:1035-1037.
    PubMed    
    
    
    
74. KWOK CS, Wong CW, Kontopantelis E, Barac A, et al
    Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA.
    Eur Heart J. 2021;42:1019-1034.
    PubMed     Abstract available
    
    
    
75. DIBIE A, Landolff Q, Veugeois A, Amabile N, et al
    Chimney technique in a TAVR-in-TAVR procedure with high risk of left main artery ostium occlusion.
    Eur Heart J. 2021;42:1051.
    PubMed    
    
    
    February 2021
76. SCHOENRATH F, Just IA, Falk V, Emmert MY, et al
    Antiplatelet and direct oral anticoagulation management after coronary artery bypass graft surgery: the Cinderella of current cardiovascular trials, please show me (some) evidence.
    Eur Heart J. 2021 Feb 22. pii: 6146041. doi: 10.1093.
    PubMed    
    
    
    
77. CAO D, Baber U, Mehran R
    Aspirin-free strategies: a framework to reassess the role of dual antiplatelet therapy after percutaneous coronary intervention.
    Eur Heart J. 2021 Feb 22. pii: 6146039. doi: 10.1093.
    PubMed    
    
    
    
78. LIUZZO G, Patrono C
    When less is more: dual antiplatelet therapy in elective percutaneous coronary intervention.
    Eur Heart J. 2021 Feb 8. pii: 6130737. doi: 10.1093.
    PubMed    
    
    
    January 2021
79. VAN DER SANGEN NMR, Rozemeijer R, Chan Pin Yin DRPP, Valgimigli M, et al
    Patient-tailored antithrombotic therapy following percutaneous coronary intervention.
    Eur Heart J. 2021 Jan 29. pii: 6122862. doi: 10.1093/eurheartj/ehaa1097.
    PubMed     Abstract available
    
    
    
80. LUNARDI M, Onuma Y, Serruys PW
    Ticagrelor monotherapy following percutaneous coronary intervention for acute coronary syndrome in TWILIGHT patients: still a future for aspirin?
    Eur Heart J. 2021 Jan 27. pii: 6121205. doi: 10.1093.
    PubMed    
    
    
    
81. VRACHATIS DA, Giannopoulos GV, Deftereos SG
    Colchicine administered early in acute myocardial infarction: ready, set ... go?
    Eur Heart J. 2021 Jan 22. pii: 6106966. doi: 10.1093.
    PubMed    
    
    
    
82. NARDAI S, Lanzer P, Abelson M, Baumbach A, et al
    Interdisciplinary management of acute ischaemic stroke: Current evidence training requirements for endovascular stroke treatment: Position Paper from the ESC Council on Stroke and the European Association for Percutaneous Cardiovascular Interventions
    Eur Heart J. 2021;42:298-307.
    PubMed     Abstract available
    
    
    
83. BERGMARK BA, Morrow DA
    Cardiac troponin elevation after elective PCI: adding infarct to major injury.
    Eur Heart J. 2021;42:335-338.
    PubMed    
    
    
    
84. O'DONOGHUE ML, Sabatine MS
    Aspirin or P2Y12 inhibition: establishing the cornerstone of antiplatelet therapy after stenting.
    Eur Heart J. 2021;42:320-322.
    PubMed    
    
    
    
85. GOPALAMURUGAN AB, Anantharaman R, Abubacker M, Varshaa GM, et al
    First-in-man proof of feasibility: PCI, TAVR, and TEVAR of aortic arch with a hybrid approach through a trans-caval (cavo-aortic) access in the same procedure.
    Eur Heart J. 2021;42:357.
    PubMed    
    
    
    
86. GUPTA A, Chhikara S
    Significant pinching of dominant left circumflex artery during provisional left main bifurcation angioplasty: what next?
    Eur Heart J. 2021;42:285.
    PubMed    
    
    
    
87. DAVIES A, Fox K, Galassi AR, Banai S, et al
    Management of refractory angina: an update.
    Eur Heart J. 2021;42:269-283.
    PubMed     Abstract available
    
    
    
88. ABDELWAHED YS, Wurster TH, Landmesser U, Leistner DM, et al
    Culprit mistaken: development of a traumatic coronary aneurysm after mismatched culprit lesion-PCI for plaque rupture.
    Eur Heart J. 2021;42:287.
    PubMed    
    
    
    
89. NICHOLLS M
    The Year in Cardiovascular Medicine 2020: Coronary Intervention.
    Eur Heart J. 2021 Jan 17. pii: 6103209. doi: 10.1093/eurheartj/ehaa1021.
    PubMed    
    
    
    
90. HOLT A, Blanche P, Zareini B, Rajan D, et al
    Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study.
    Eur Heart J. 2021 Jan 11. pii: 6082772. doi: 10.1093/eurheartj/ehaa1058.
    PubMed     Abstract available
    
    
    December 2020
91. CAO D, Chandiramani R, Chiarito M, Claessen BE, et al
    Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey.
    Eur Heart J. 2020 Dec 26. pii: 6050475. doi: 10.1093.
    PubMed     Abstract available
    
    
    
92. CORTESE F, Magli M, Di Marino S
    A floating thrombus in the ascending aorta, as a complication of a percutaneous coronary angiography.
    Eur Heart J. 2020 Dec 14. pii: 6034852. doi: 10.1093/eurheartj/ehaa1001.
    PubMed    
    
    
    
93. GIACOPPO D, Matsuda Y, Fovino LN, D'Amico G, et al
    Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized cl
    Eur Heart J. 2020 Dec 7. pii: 6025040. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2020
94. SILVAIN J, Zeitouni M, Paradies V, Zheng HL, et al
    Cardiac procedural myocardial injury, infarction, and mortality in patients undergoing elective percutaneous coronary intervention: a pooled analysis of patient-level data.
    Eur Heart J. 2020 Nov 30. pii: 6012927. doi: 10.1093.
    PubMed     Abstract available
    
    
    
95. PATRONO C, Galiuto L
    Weak hypothesis? Wrong pharmacologic tool? Inadequate experimental design? Comment on the ATPCI trial.
    Eur Heart J. 2020;41:4166-4167.
    PubMed    
    
    
    
96. GUO TT, Tan JS, Wu Y, Gao X, et al
    Balloon pulmonary angioplasty with distal embolic protection device for chronic thromboembolic pulmonary hypertension.
    Eur Heart J. 2020 Nov 12. pii: 5979515. doi: 10.1093.
    PubMed    
    
    
    
97. VERDECCHIA P, Angeli F, Cavallini C
    Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation and coexistent atrial fibrillation.
    Eur Heart J. 2020 Nov 9. pii: 5964168. doi: 10.1093.
    PubMed    
    
    
    October 2020
98. FANAROFF AC, Lopes RD
    Antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: balance best with double antithrombotic therapy.
    Eur Heart J. 2020 Oct 25. pii: 5939783. doi: 10.1093.
    PubMed    
    
    
    
99. CHEN SL
    In the face of cunning enemy: DK crush writes legend.
    Eur Heart J. 2020;41:3763-3764.
    PubMed    
    
    
    
100. STOREY RF
     The long journey of individualizing antiplatelet therapy after acute coronary syndromes.
     Eur Heart J. 2020;41:3546-3548.
     PubMed    
     
     
     
101. BABER U, Dangas G, Angiolillo DJ, Cohen DJ, et al
     Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS.
     Eur Heart J. 2020;41:3533-3545.
     PubMed     Abstract available
     
     
     September 2020
102. WALTERSCHEID B, Nguyen J, Tarbox M, Eshak N, et al
     Clopidogrel-induced sweet syndrome: severe dermatological complication after percutaneous coronary intervention.
     Eur Heart J. 2020 Sep 4. pii: 5901663. doi: 10.1093.
     PubMed    
     
     
     August 2020
103. VRANCKX P, Valgimigli M, Eckardt L, Lewalter T, et al
     Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial.
     Eur Heart J. 2020 Aug 29. pii: 5898835. doi: 10.1093.
     PubMed     Abstract available
     
     
     July 2020
104. HOWARD JP, Arnold AD, Ahmad Y
     Bias, heterogeneity, and uncertainty in meta-analysis.
     Eur Heart J. 2020;41:2712.
     PubMed    
     
     
     
105. LIISTRO F, Di Mario C
     Paclitaxel-coated balloons in peripheral artery disease: how much is enough?
     Eur Heart J. 2020;41:2553-2555.
     PubMed    
     
     
     
106. SADEGHI AH, Taverne YJHJ, Bogers AJJC, Mahtab EAF, et al
     Immersive virtual reality surgical planning of minimally invasive coronary artery bypass for Kawasaki disease.
     Eur Heart J. 2020 Jul 8. pii: 5868577. doi: 10.1093.
     PubMed    
     
     
     
107. FERENC M, Neumann FJ
     Towards a lesion-specific approach to percutaneous coronary intervention for bifurcation lesions.
     Eur Heart J. 2020 Jul 3. pii: 5866891. doi: 10.1093.
     PubMed    
     
     
     June 2020
108. JAYARAJ R, Kumaraswamy C, Shaw P
     Clinical and conceptual approaches to interpreting the findings of systematic review and meta-analysis of mortality after drug-eluting stents vs. coronary artery bypass grafting for left main coronary artery disease.
     Eur Heart J. 2020 Jun 26. pii: 5863013. doi: 10.1093.
     PubMed    
     
     
     
109. JOBS A, Schwarzer G, Thiele H
     Conclusions of complete revascularization meta-analysis are challenged by state-of-the-art methods.
     Eur Heart J. 2020;41:2223-2224.
     PubMed    
     
     
     May 2020
110. SCHMIADY MO, Sromicki J, Kucher N, Ouda A, et al
     Successful percutaneous thrombectomy in a patient with COVID-19 pneumonia and acute pulmonary embolism supported by extracorporeal membrane oxygenation.
     Eur Heart J. 2020 May 12. pii: 5836253. doi: 10.1093.
     PubMed    
     
     
     
111. GAUDINO M, Freemantle N, Farkouh ME
     The conundrum of the treatment for left main coronary disease.
     Eur Heart J. 2020 May 5. pii: 5830808. doi: 10.1093.
     PubMed    
     
     
     
112. BJORNSTAD JL, Bendz B
     Periprocedural myocardial injury in the EXCEL trial.
     Eur Heart J. 2020;41:1703.
     PubMed    
     
     
     
113. GARGIULO G, Goette A, Vranckx P, Valgimigli M, et al
     Higher risk of stent thrombosis with double therapy with direct oral anticoagulants: cherry picking the populations of interest does not help.
     Eur Heart J. 2020;41:1701-1702.
     PubMed    
     
     
     April 2020
114. HAN Y
     A treatment strategy for acute myocardial infarction and personal protection for medical staff during the COVID-19 epidemic: the Chinese experience.
     Eur Heart J. 2020 Apr 27. pii: 5825637. doi: 10.1093.
     PubMed    
     
     
     March 2020
115. STONE GW, Ben-Yehuda O, Sabik JF, Kappetein AP, et al
     Considerations for an optimal definition of procedural myocardial infarction.
     Eur Heart J. 2020 Mar 30. pii: 5813684. doi: 10.1093.
     PubMed    
     
     
     
116. AHMAD Y, Howard JP, Arnold AD, Cook CM, et al
     Mortality after drug-eluting stents vs. coronary artery bypass grafting for left main coronary artery disease: a meta-analysis of randomized controlled trials.
     Eur Heart J. 2020 Mar 2. pii: 5771278. doi: 10.1093.
     PubMed     Abstract available
     
     
     February 2020
117. ALLAHYARI A, Jernberg T, Hagstrom E, Leosdottir M, et al
     Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study.
     Eur Heart J. 2020 Feb 18. pii: 5739477. doi: 10.1093.
     PubMed     Abstract available
     
     
     
118. SINNAEVE P, Van de Werf F
     Primary PCI and the indistinct 120 min time limit.
     Eur Heart J. 2020;41:867-869.
     PubMed    
     
     
     
119. AGASTHI P, Tseng A, Mulpuru SK
     Appropriate cohort selection and its impact on a meta-analysis evaluating the efficacy of direct oral anticoagulants post-percutaneous coronary intervention.
     Eur Heart J. 2020 Feb 14. pii: 5736264. doi: 10.1093.
     PubMed    
     
     
     
120. RYMER JA, Granger CB
     Managing patients with ST-elevation myocardial infarction and multivessel disease: is the story complete?
     Eur Heart J. 2020 Feb 7. pii: 5729984. doi: 10.1093.
     PubMed    
     
     
     
121. RAMASAMY A, Bajaj R, Choudry FA, Pugliese F, et al
     Intravascular ultrasound-guided management of ST-elevation myocardial infarction in a patient with lung cancer and myocardial metastasis.
     Eur Heart J. 2020 Feb 7. pii: 5729982. doi: 10.1093.
     PubMed    
     
     
     January 2020
122. KONSTANTINIDES SV, Meyer G, Becattini C, Bueno H, et al
     2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS).
     Eur Heart J. 2020;41:543-603.
     PubMed    
     
     
     
123. IANNACCONE M, Brilakis ES, Boccuzzi GG
     An App for complex PCI solutions.
     Eur Heart J. 2020;41:342-344.
     PubMed    
     
     
     
124. ALI ZA, McEntegart M, Hill JM, Spratt JC, et al
     Intravascular lithotripsy for treatment of stent underexpansion secondary to severe coronary calcification.
     Eur Heart J. 2020;41:485-486.
     PubMed    
     
     
     December 2019
125. PAVASINI R, Biscaglia S, Barbato E, Tebaldi M, et al
     Complete revascularization reduces cardiovascular death in patients with ST-segment elevation myocardial infarction and multivessel disease: systematic review and meta-analysis of randomized clinical trials.
     Eur Heart J. 2019 Dec 31. pii: 5692630. doi: 10.1093.
     PubMed     Abstract available
     
     
     
126. STOREY RF, Valgimigli M, Cuisset T, Capodanno D, et al
     Intolerance to aspirin in patients undergoing percutaneous coronary intervention in the setting of chronic coronary syndromes: perspectives from the ESC 2019 Chronic Coronary Syndromes guidelines.
     Eur Heart J. 2019 Dec 23. pii: 5686014. doi: 10.1093.
     PubMed    
     
     
     
127. WELSH RC
     Applying evidence-based antiplatelet therapy in patients following a myocardial infarction without percutaneous coronary revascularization.
     Eur Heart J. 2019 Dec 23. pii: 5686009. doi: 10.1093.
     PubMed    
     
     
     
128. KOGAME N, Serruys PW, Onuma Y
     Cracking (the code of) coronary artery calcification to win the last battle of percutaneous coronary intervention: still in the middle of a rocky road.
     Eur Heart J. 2019 Dec 23. pii: 5686015. doi: 10.1093.
     PubMed    
     
     
     
129. KALLA M, Hao G, Tapoulal N, Tomek J, et al
     The cardiac sympathetic co-transmitter neuropeptide Y is pro-arrhythmic following ST-elevation myocardial infarction despite beta-blockade.
     Eur Heart J. 2019 Dec 13. pii: 5675548. doi: 10.1093.
     PubMed     Abstract available
     
     
     
130. LOPEZ-JIMENEZ F, Gersh BJ
     Secondary prevention after coronary artery bypass grafting saves lives: a golden opportunity often wasted.
     Eur Heart J. 2019 Dec 4. pii: 5651910. doi: 10.1093.
     PubMed    
     
     
     
131. BHARADWAJ A, Potts J, Mohamed MO, Parwani P, et al
     Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA.
     Eur Heart J. 2019 Dec 4. pii: 5652220. doi: 10.1093.
     PubMed     Abstract available
     
     
     November 2019
132. LOPES RD, Hong H, Alexander JH
     Antithrombotic therapy after acute coronary syndrome and/or percutaneous coronary intervention in atrial fibrillation: finding the sweet spot.
     Eur Heart J. 2019 Nov 27. pii: 5644218. doi: 10.1093.
     PubMed    
     
     
     
133. LUSCHER TF
     Optimizing heart failure management: anticoagulation, diuretic withdrawal, iron substitution, and novel inotropes.
     Eur Heart J. 2019;40:3579-3582.
     PubMed    
     
     
     October 2019
134. GARGIULO G, Goette A, Tijssen J, Eckardt L, et al
     Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based rand
     Eur Heart J. 2019 Oct 25. pii: 5607287. doi: 10.1093.
     PubMed     Abstract available
     
     
     
135. BJORKLUND E, Nielsen SJ, Hansson EC, Karlsson M, et al
     Secondary prevention medications after coronary artery bypass grafting and long-term survival: a population-based longitudinal study from the SWEDEHEART registry.
     Eur Heart J. 2019 Oct 22. pii: 5602556. doi: 10.1093.
     PubMed     Abstract available
     
     
     
136. IBANEZ B
     And fibrinolysis became pharmacoinvasive.
     Eur Heart J. 2019 Oct 12. pii: 5586502. doi: 10.1093.
     PubMed    
     
     
     September 2019
137. DANCHIN N, Popovic B, Puymirat E, Goldstein P, et al
     Five-year outcomes following timely primary percutaneous intervention, late primary percutaneous intervention, or a pharmaco-invasive strategy in ST-segment elevation myocardial infarction: the FAST-MI programme.
     Eur Heart J. 2019 Sep 20. pii: 5572227. doi: 10.1093.
     PubMed     Abstract available
     
     
     
138. THRANE PG, Kristensen SD, Olesen KKW, Mortensen LS, et al
     16-year follow-up of the Danish Acute Myocardial Infarction 2 (DANAMI-2) trial: primary percutaneous coronary intervention vs. fibrinolysis in ST-segment elevation myocardial infarction.
     Eur Heart J. 2019 Sep 2. pii: 5554441. doi: 10.1093.
     PubMed     Abstract available
     
     
     August 2019
139. LUSCHER TF
     Refining percutaneous coronary intervention: intracoronary imaging, haemodynamics, P2Y12 antagonists, and public outcomes reporting.
     Eur Heart J. 2019;40:2549-2552.
     PubMed    
     
     
     
140. SERRUYS PW, Takahashi K, Chichareon P, Kogame N, et al
     Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial.
     Eur Heart J. 2019;40:2595-2604.
     PubMed     Abstract available
     
     
     
141. LE PAGE PT, Bellenger NG
     Completeness of revascularization: should we not consider assessment before and after coronary artery bypass grafting?
     Eur Heart J. 2019 Aug 7. pii: 5544747. doi: 10.1093.
     PubMed    
     
     
     
142. CALISKAN E, Falk V, Emmert MY
     Multiarterial grafting in coronary artery bypass grafting.
     Eur Heart J. 2019;40:2479-2481.
     PubMed    
     
     
     July 2019
143. THIELE H, Ohman EM, de Waha-Thiele S, Zeymer U, et al
     Management of cardiogenic shock complicating myocardial infarction: an update 2019.
     Eur Heart J. 2019 Jul 4. pii: 5528526. doi: 10.1093.
     PubMed     Abstract available
     
     
     June 2019
144. KOTECHA D, Castella M
     Is it time to treat post-operative atrial fibrillation just like regular atrial fibrillation?
     Eur Heart J. 2019 Jun 25. pii: 5523037. doi: 10.1093.
     PubMed    
     
     
     May 2019
145. SCHUNKERT H, Boening A, von Scheidt M, Lanig C, et al
     Randomized trial of ticagrelor vs. aspirin in patients after coronary artery bypass grafting: the TiCAB trial.
     Eur Heart J. 2019 May 30. pii: 5506732. doi: 10.1093.
     PubMed     Abstract available
     
     
     
146. URBAN P, Mehran R, Colleran R, Angiolillo DJ, et al
     Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk.
     Eur Heart J. 2019 May 22. pii: 5492739. doi: 10.1093.
     PubMed     Abstract available
     
     
     
147. MYERS PO, Nguyen-Tang T, Alibegovic-Zaza J, Inan I, et al
     Spontaneous haemorrhage on apixaban masquerading as obstructive cholangitis after heart surgery.
     Eur Heart J. 2019 May 9. pii: 5487606. doi: 10.1093.
     PubMed    
     
     
     
148. GATZOULIS KA, Tsiachris D, Arsenos P, Antoniou CK, et al
     Arrhythmic risk stratification in post-myocardial infarction patients with preserved ejection fraction: the PRESERVE EF study.
     Eur Heart J. 2019 May 3. pii: 5485105. doi: 10.1093.
     PubMed     Abstract available
     
     
     April 2019
149. JONES DA, Rathod KS, Koganti S, Lim P, et al
     The association between the public reporting of individual operator outcomes with patient profiles, procedural management, and mortality after percutaneous coronary intervention: an observational study from the Pan-London PCI (BCIS) Registry using an
     Eur Heart J. 2019 Apr 10. pii: 5443278. doi: 10.1093.
     PubMed     Abstract available
     
     
     
150. MEHRAN R, Kalkman DN, Angiolillo DJ
     Atrial fibrillation, with ACS and PCI: walking a tightrope.
     Eur Heart J. 2019 Apr 8. pii: 5431179. doi: 10.1093.
     PubMed    
     
     
     March 2019
151. BEN-YEHUDA O, Chen S, Redfors B, McAndrew T, et al
     Impact of large periprocedural myocardial infarction on mortality after percutaneous coronary intervention and coronary artery bypass grafting for left main disease: an analysis from the EXCEL trial.
     Eur Heart J. 2019 Mar 28. pii: 5421317. doi: 10.1093.
     PubMed     Abstract available
     
     
     
152. PIAYDA K, Veulemans V, Kelm M, Zeus T, et al
     Transcaval aortic valve implantation through a partially thrombosed infrarenal aortic aneurysm.
     Eur Heart J. 2019 Mar 27. pii: 5420568. doi: 10.1093.
     PubMed    
     
     
     
153. GRABHER F, Hamm W, Massberg S, Orban M, et al
     Uncommon cause of progressive dyspnoea 12 years after coronary artery bypass surgery.
     Eur Heart J. 2019 Mar 12. pii: 5377349. doi: 10.1093.
     PubMed    
     
     
     
154. HERRING N, Tapoulal N, Kalla M, Ye X, et al
     Neuropeptide-Y causes coronary microvascular constriction and is associated with reduced ejection fraction following ST-elevation myocardial infarction.
     Eur Heart J. 2019 Mar 11. pii: 5374846. doi: 10.1093.
     PubMed     Abstract available
     
     
     
155. REDFORS B, Dworeck C, Haraldsson I, Angeras O, et al
     Pretreatment with P2Y12 receptor antagonists in ST-elevation myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry.
     Eur Heart J. 2019 Mar 9. pii: 5372330. doi: 10.1093.
     PubMed     Abstract available
     
     
     
156. RABER L, Yamaji K, Kelbaek H, Engstrom T, et al
     Five-year clinical outcomes and intracoronary imaging findings of the COMFORTABLE AMI trial: randomized comparison of biodegradable polymer-based biolimus-eluting stents with bare-metal stents in patients with acute ST-segment elevation myocardial inf
     Eur Heart J. 2019 Mar 9. pii: 5372331. doi: 10.1093.
     PubMed     Abstract available
     
     
     February 2019
157. OLDGREN J, Steg PG, Hohnloser SH, Lip GYH, et al
     Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
     Eur Heart J. 2019 Feb 21. pii: 5359476. doi: 10.1093.
     PubMed     Abstract available
     
     
     
158. TURGEON RD, Althouse AD
     Inappropriate inclusion of multiple studies in a meta-analysis of randomized controlled trials of atorvastatin loading prior to percutaneous coronary intervention for acute coronary syndrome.
     Eur Heart J. 2019 Feb 20. pii: 5345134. doi: 10.1093.
     PubMed    
     
     
     
159. LUSCHER TF, Davies A
     Inclusion of multiple inappropriate studies in a meta-analysis of randomized controlled trials of atorvastatin loading prior to percutaneous coronary intervention for acute coronary syndrome: editor's response.
     Eur Heart J. 2019 Feb 20. pii: 5345135. doi: 10.1093.
     PubMed    
     
     
     January 2019
160. CREA F, Bairey Merz CN, Beltrame JF, Berry C, et al
     Mechanisms and diagnostic evaluation of persistent or recurrent angina following percutaneous coronary revascularization.
     Eur Heart J. 2019 Jan 4. pii: 5273474. doi: 10.1093.
     PubMed     Abstract available
     
     
     
161. YOSHIKAWA Y, Kimura T
     Percutaneous coronary intervention in stable coronary artery disease: still in equipoise?
     Eur Heart J. 2019 Jan 2. pii: 5272354. doi: 10.1093.
     PubMed    
     
     
     
162. DUDEK D, Dziewierz A, Stone G, Wijns W, et al
     The year in cardiology 2018: coronary interventions.
     Eur Heart J. 2019 Jan 2. pii: 5265297. doi: 10.1093.
     PubMed    
     
     
     December 2018
163. ZIMMERMANN FM, Omerovic E, Fournier S, Kelbaek H, et al
     Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data.
     Eur Heart J. 2018 Dec 28. pii: 5265290. doi: 10.1093.
     PubMed     Abstract available
     
     
     
164. BYRNE RA, Alfonso F, Schneider S, Maeng M, et al
     Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction
     Eur Heart J. 2018 Dec 5. pii: 5231946. doi: 10.1093.
     PubMed     Abstract available
     
     
     November 2018
165. POTTS JE, Iliescu CA, Lopez Mattei JC, Martinez SC, et al
     Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States.
     Eur Heart J. 2018 Nov 30. pii: 5221009. doi: 10.1093.
     PubMed     Abstract available
     
     
     
166. KLOK FA, Pruefer D, Rolf A, Konstantinides SV, et al
     Magnetic resonance direct thrombus imaging for pre-operative assessment of acute thrombosis in chronic thromboembolic pulmonary hypertension.
     Eur Heart J. 2018 Nov 27. pii: 5211203. doi: 10.1093.
     PubMed    
     
     
     October 2018
167. FARAG M, Spinthakis N, Gue YX, Srinivasan M, et al
     Impaired endogenous fibrinolysis in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention is a predictor of recurrent cardiovascular events: the RISK PPCI study.
     Eur Heart J. 2018 Oct 30. pii: 5149701. doi: 10.1093.
     PubMed     Abstract available
     
     
     August 2018
168. WINDECKER S, Neumann FJ, Juni P, Sousa-Uva M, et al
     Considerations for the choice between coronary artery bypass grafting and percutaneous coronary intervention as revascularization strategies in major categories of patients with stable multivessel coronary artery disease: an accompanying article of th
     Eur Heart J. 2018 Aug 25. pii: 5077827. doi: 10.1093.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Vascular Surgery is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: